lorazepam has been researched along with Critical Illness in 35 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this report is to describe the use of flumazenil as a diagnostic aid in the differential diagnosis of coma in a patient with an inadvertent overdose of benzodiazepines." | 7.69 | Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient. ( McLachlan, RS; Sharpe, MD; Sprenger, H, 1994) |
| "Pharmacokinetic data were evaluated in 10 term neonates with seizures after intravenous administration of lorazepam, 0." | 7.68 | Pharmacokinetics of lorazepam in critically ill neonates with seizures. ( Kowalczyk, AL; Mangurten, HH; McDermott, CA; Metrick, S; Rodvold, KA; Schnitzler, ER, 1992) |
| "We hypothesized that higher plasma concentrations of lorazepam are associated with increased delirium risk, whereas higher plasma concentrations of dexmedetomidine are associated with reduced delirium risk." | 5.27 | Sedative Plasma Concentrations and Delirium Risk in Critical Illness. ( Ely, EW; Ferrell, BA; Girard, TD; Hughes, CG; Pandharipande, PP; Patel, MB; Scheinin, M; Shintani, AK; Stollings, JL; Thompson, JL; Wilkinson, GR, 2018) |
| " Serum propylene glycol concentrations were drawn at 48 hrs into the high-dose lorazepam infusion, and the presence of propylene glycol accumulation, as evidenced by a high anion gap (> or =15 mmol/L) metabolic acidosis with elevated osmol gap (> or =10 mOsm/L), was assessed at that time." | 5.11 | Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. ( Arroliga, AC; Gonzales, JP; McCarthy, K; Shehab, N, 2004) |
| " Delirium and daily dosage of lorazepam are the factors independently associated to extremely severe REM sleep reduction." | 3.77 | Sleep disturbances in the critically ill patients: role of delirium and sedative agents. ( Bosma, K; Braghiroli, A; Locane, MD; Mascia, L; Ranieri, VM; Trompeo, AC; Vidi, Y, 2011) |
| "The purpose of this report is to describe the use of flumazenil as a diagnostic aid in the differential diagnosis of coma in a patient with an inadvertent overdose of benzodiazepines." | 3.69 | Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient. ( McLachlan, RS; Sharpe, MD; Sprenger, H, 1994) |
| "The benzodiazepine/morphine combination produced apnea and diminished respiratory effort in patients requiring sedation from 2 to 50 days, including those with hemodynamic instability, hepatic dysfunction, renal dysfunction, and sepsis." | 3.69 | A method to produce sedation in critically ill patients. ( Johnson, M; Watling, SM; Yanos, J, 1996) |
| "Pharmacokinetic data were evaluated in 10 term neonates with seizures after intravenous administration of lorazepam, 0." | 3.68 | Pharmacokinetics of lorazepam in critically ill neonates with seizures. ( Kowalczyk, AL; Mangurten, HH; McDermott, CA; Metrick, S; Rodvold, KA; Schnitzler, ER, 1992) |
| "The objective of the present investigation was to develop a population pharmacodynamic model for midazolam- and lorazepam-induced sedation upon long-term continuous infusion in critically ill patients." | 2.72 | Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. ( Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP, 2006) |
| " There were no significant differences in demographic variables, lorazepam dosage or other sedative therapy, or lorazepam serum concentrations between patients with withdrawal and those without withdrawal." | 2.72 | Withdrawal from lorazepam in critically ill children. ( Coleman, DM; Crowley, MR; Dominguez, KD; Katz, RW; Kelly, HW; Wilkins, DG, 2006) |
| " Population pharmacokinetic models were developed using the Non-Linear Mixed Effect Modelling (NONMEM) program." | 2.71 | Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ( Danhof, M; de Jongh, J; Strack van Schijndel, RM; Swart, EL; Thijs, LG; Zuideveld, KP, 2004) |
| " The mean number of dosage changes per day was 7." | 2.69 | Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: a prospective, randomized comparison. ( Byrne, TK; McCollam, JS; Norcross, ED; O'Neil, MG; Reeves, ST, 1999) |
| "Midazolam-treated patients used significantly larger amounts of drug for similar levels of sedation and anxiolysis (14." | 2.68 | Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. ( Boysen, PG; Cernaianu, AC; Cilley, JH; DelRossi, AJ; Flum, DR; Grosso, MA; Ross, SE; Vassilidze, TV, 1996) |
| "The pharmacokinetic (PK) parameters of many drugs are altered as a consequence of the pathophysiological changes associated with critical illness." | 2.58 | Altered Pharmacokinetics in Prolonged Infusions of Sedatives and Analgesics Among Adult Critically Ill Patients: A Systematic Review. ( Joynt, GM; Lee, A; Ling, L; Tse, AHW, 2018) |
| "The diagnosis and management of catatonia in the critically ill patient raises unique challenges." | 2.50 | Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. a case series and review of the literature*. ( Berg, SM; Bittner, EA; Nejad, SH; Saddawi-Konefka, D, 2014) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| "Propofol has superior value compared with lorazepam when used for sedation among the critically ill who require mechanical ventilation when used in the setting of daily sedative interruption." | 2.44 | Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. ( Campbell-Bright, S; Carson, SS; Cox, CE; Govert, JA; Kress, JP; Reed, SD; Rodgers, JE, 2008) |
| " A protocol incorporating SAS scoring and symptom-triggered benzodiazepine dosing was implemented in place of a protocol that utilized the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale and fixed benzodiazepine dosing." | 1.46 | A Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill. ( Dargin, J; Gray, A; Grgurich, P; Lei, Y; Sen, S; Smith-Freedman, A; Tulolo, A, 2017) |
| " The most common diazepam dosage was 10 mg every 6 hours, and individual doses ranged from 5 to 30 mg." | 1.37 | Diazepam as a component of goal-directed sedation in critically ill trauma patients. ( Birrer, KL; Cheatham, ML; Dasta, JF; Gesin, G; Kane-Gill, SL; Kolnik, LJ, 2011) |
| "Propylene glycol accumulation was defined as concentrations of 25 mg/dL or more." | 1.35 | Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions. ( Fish, DN; Horinek, EL; Kiser, TH; MacLaren, R, 2009) |
| "Propofol was least costly in 86% of the short-term simulations, midazolam was least costly in 97." | 1.33 | Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients. ( MacLaren, R; Sullivan, PW, 2005) |
| "Midazolam was successfully discontinued in 24 (80%) patients in 3 days (median), and adequate and appropriate sedation was maintained with lorazepam monotherapy." | 1.30 | A cost analysis of enterally administered lorazepam in the pediatric intensive care unit. ( Cash, J; Chester, EA; Grant, MJ; Lugo, RA; Vernon, DD, 1999) |
| "In critically ill patients in respiratory failure, neuromuscular paralysis decreased whole body oxygen consumption and increased pHi." | 1.29 | The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients. ( Kaufman, D; Marik, PE, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (22.86) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Shudofsky, KN | 1 |
| Janssen, PKC | 1 |
| Foudraine, N | 1 |
| le Noble, JLML | 1 |
| Wang, K | 1 |
| Zhang, Z | 1 |
| Yu, M | 1 |
| Tao, Y | 1 |
| Xie, M | 1 |
| Stollings, JL | 1 |
| Thompson, JL | 1 |
| Ferrell, BA | 1 |
| Scheinin, M | 1 |
| Wilkinson, GR | 1 |
| Hughes, CG | 1 |
| Shintani, AK | 1 |
| Ely, EW | 1 |
| Girard, TD | 2 |
| Pandharipande, PP | 1 |
| Patel, MB | 1 |
| Tse, AHW | 1 |
| Ling, L | 1 |
| Lee, A | 1 |
| Joynt, GM | 1 |
| Mistraletti, G | 1 |
| Mantovani, ES | 1 |
| Cadringher, P | 1 |
| Cerri, B | 1 |
| Corbella, D | 1 |
| Umbrello, M | 1 |
| Anania, S | 1 |
| Andrighi, E | 1 |
| Barello, S | 1 |
| Di Carlo, A | 1 |
| Martinetti, F | 1 |
| Formenti, P | 1 |
| Spanu, P | 1 |
| Iapichino, G | 1 |
| Saddawi-Konefka, D | 1 |
| Berg, SM | 1 |
| Nejad, SH | 1 |
| Bittner, EA | 1 |
| Chen, K | 1 |
| Lu, Z | 1 |
| Xin, YC | 1 |
| Cai, Y | 1 |
| Chen, Y | 1 |
| Pan, SM | 1 |
| Haddad, SH | 1 |
| Gonzales, CB | 1 |
| Deeb, AM | 1 |
| Tamim, HM | 1 |
| AlDawood, AS | 1 |
| Al Babtain, I | 1 |
| Naidu, BS | 1 |
| Arabi, YM | 1 |
| Stewart, R | 1 |
| Perez, R | 1 |
| Musial, B | 1 |
| Lukens, C | 1 |
| Adjepong, YA | 1 |
| Manthous, CA | 1 |
| Gagnon, DJ | 1 |
| Fontaine, GV | 1 |
| Smith, KE | 1 |
| Riker, RR | 1 |
| Miller, RR | 1 |
| Lerwick, PA | 1 |
| Lucas, FL | 1 |
| Dziodzio, JT | 1 |
| Sihler, KC | 1 |
| Fraser, GL | 1 |
| Sen, S | 1 |
| Grgurich, P | 1 |
| Tulolo, A | 1 |
| Smith-Freedman, A | 1 |
| Lei, Y | 1 |
| Gray, A | 1 |
| Dargin, J | 1 |
| Horinek, EL | 1 |
| Kiser, TH | 1 |
| Fish, DN | 1 |
| MacLaren, R | 2 |
| Kress, JP | 2 |
| Gesin, G | 1 |
| Kane-Gill, SL | 1 |
| Dasta, JF | 2 |
| Birrer, KL | 1 |
| Kolnik, LJ | 1 |
| Cheatham, ML | 1 |
| Trompeo, AC | 1 |
| Vidi, Y | 1 |
| Locane, MD | 1 |
| Braghiroli, A | 1 |
| Mascia, L | 1 |
| Bosma, K | 1 |
| Ranieri, VM | 1 |
| LeBlanc, JM | 1 |
| Pruchnicki, MC | 1 |
| Gerlach, A | 1 |
| Cook, C | 1 |
| Swart, EL | 2 |
| Zuideveld, KP | 2 |
| de Jongh, J | 2 |
| Danhof, M | 2 |
| Thijs, LG | 2 |
| Strack van Schijndel, RM | 2 |
| Arroliga, AC | 1 |
| Shehab, N | 1 |
| McCarthy, K | 1 |
| Gonzales, JP | 1 |
| Jacobi, J | 1 |
| Bouchard, NC | 1 |
| Fulton, JA | 1 |
| Hoffman, RS | 1 |
| Sullivan, PW | 1 |
| Dominguez, KD | 1 |
| Crowley, MR | 1 |
| Coleman, DM | 1 |
| Katz, RW | 1 |
| Wilkins, DG | 1 |
| Kelly, HW | 1 |
| Cox, CE | 1 |
| Reed, SD | 1 |
| Govert, JA | 1 |
| Rodgers, JE | 1 |
| Campbell-Bright, S | 1 |
| Carson, SS | 1 |
| Sprenger, H | 1 |
| Sharpe, MD | 1 |
| McLachlan, RS | 1 |
| Cernaianu, AC | 1 |
| DelRossi, AJ | 1 |
| Flum, DR | 1 |
| Vassilidze, TV | 1 |
| Ross, SE | 1 |
| Cilley, JH | 1 |
| Grosso, MA | 1 |
| Boysen, PG | 1 |
| Marik, PE | 1 |
| Kaufman, D | 1 |
| Watling, SM | 1 |
| Johnson, M | 1 |
| Yanos, J | 1 |
| Schulman, SR | 1 |
| Lugo, RA | 1 |
| Chester, EA | 1 |
| Cash, J | 1 |
| Grant, MJ | 1 |
| Vernon, DD | 1 |
| McCollam, JS | 1 |
| O'Neil, MG | 1 |
| Norcross, ED | 1 |
| Byrne, TK | 1 |
| Reeves, ST | 1 |
| Buczko, GB | 1 |
| Maze, M | 1 |
| Scarfini, C | 1 |
| Cavaliere, F | 1 |
| McDermott, CA | 1 |
| Kowalczyk, AL | 1 |
| Schnitzler, ER | 1 |
| Mangurten, HH | 1 |
| Rodvold, KA | 1 |
| Metrick, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status[NCT00095251] | Phase 2 | 100 participants (Anticipated) | Interventional | 2004-08-31 | Completed | ||
| Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients[NCT01360346] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias[NCT04250376] | 100 participants (Anticipated) | Interventional | 2017-11-27 | Enrolling by invitation | |||
| Lymphatic System Health in Alzheimer's Disease[NCT04205539] | Phase 1 | 0 participants (Actual) | Interventional | 2021-12-10 | Withdrawn (stopped due to Pending COVID-19 pandemic) | ||
| Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation in ICU: a Randomized Controlled Trial[NCT05718024] | Phase 4 | 174 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Impact of Dexmedetomidine Supplemented Analgesia on Sleep Quality in Elderly Patients After Major Surgery: A Randomized, Double-blind, and Placebo-controlled Pilot Study[NCT03117790] | Phase 4 | 118 participants (Actual) | Interventional | 2017-06-26 | Completed | ||
| Impact of Low-Dose Dexmedetomidine on Sleep Quality in Mechanical Ventilation Patients After Surgery in Intensive Care Unit: a Pilot Randomized, Double-Blind, Placebo-Controlled Trial[NCT03335527] | Phase 4 | 80 participants (Actual) | Interventional | 2017-11-17 | Completed | ||
| Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation (SATIRE Trial): A Prospective, Randomized Cohort Study[NCT03181620] | 200 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | |||
| Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant[NCT02819089] | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for lorazepam and Critical Illness
| Article | Year |
|---|---|
Altered Pharmacokinetics in Prolonged Infusions of Sedatives and Analgesics Among Adult Critically Ill Patients: A Systematic Review.
Topics: Adult; Analgesics; Critical Illness; Dexmedetomidine; Fentanyl; Humans; Hypnotics and Sedatives; Inf | 2018 |
Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. a case series and review of the literature*.
Topics: Adolescent; Aged; Anti-Anxiety Agents; Blood Chemical Analysis; Catatonia; Critical Illness; Early D | 2014 |
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Bradycardia; Clonidine; Conscious Sedation; Critical Il | 2015 |
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Bradycardia; Clonidine; Conscious Sedation; Critical Il | 2015 |
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Bradycardia; Clonidine; Conscious Sedation; Critical Il | 2015 |
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Bradycardia; Clonidine; Conscious Sedation; Critical Il | 2015 |
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation.
Topics: Cost-Benefit Analysis; Critical Illness; Decision Trees; Humans; Hypnotics and Sedatives; Lorazepam; | 2008 |
Sedation in critically ill patients: a review.
Topics: Adult; Age Factors; Aged; Analgesics; Critical Illness; Electroencephalography; Humans; Hypnotics an | 2001 |
New agents for sedation in the intensive care unit.
Topics: Adrenergic alpha-Agonists; Anti-Anxiety Agents; Critical Illness; Dexmedetomidine; Humans; Hypnotics | 2001 |
New agents for sedation in the intensive care unit.
Topics: Adrenergic alpha-Agonists; Anti-Anxiety Agents; Critical Illness; Dexmedetomidine; Humans; Hypnotics | 2001 |
New agents for sedation in the intensive care unit.
Topics: Adrenergic alpha-Agonists; Anti-Anxiety Agents; Critical Illness; Dexmedetomidine; Humans; Hypnotics | 2001 |
New agents for sedation in the intensive care unit.
Topics: Adrenergic alpha-Agonists; Anti-Anxiety Agents; Critical Illness; Dexmedetomidine; Humans; Hypnotics | 2001 |
8 trials available for lorazepam and Critical Illness
| Article | Year |
|---|---|
Sedative Plasma Concentrations and Delirium Risk in Critical Illness.
Topics: Aged; Critical Illness; Delirium; Dexmedetomidine; Female; Humans; Hypnotics and Sedatives; Intensiv | 2018 |
Enteral vs. intravenous ICU sedation management: study protocol for a randomized controlled trial.
Topics: Administration, Oral; Anesthetics, Intravenous; Clinical Protocols; Computer-Assisted Instruction; C | 2013 |
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Critical Illness; Female; Humans; Hypnotics and Sedative | 2004 |
Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults.
Topics: Acid-Base Equilibrium; Acidosis; Adult; Critical Illness; Dose-Response Relationship, Drug; Female; | 2004 |
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Chromatography, High Pressure Liquid; Conscious Sedation | 2006 |
Withdrawal from lorazepam in critically ill children.
Topics: Child, Preschool; Critical Illness; Dose-Response Relationship, Drug; Endpoint Determination; Female | 2006 |
Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Cost-Benefit Analysis; Critical Ill | 1996 |
Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: a prospective, randomized comparison.
Topics: Adolescent; Adult; Aged; Conscious Sedation; Costs and Cost Analysis; Critical Illness; Drug Costs; | 1999 |
20 other studies available for lorazepam and Critical Illness
| Article | Year |
|---|---|
Clearance of Lormetazepam, Midazolam, and Their Conjugated Metabolites by Continuous Venovenous Hemofiltration During Prolonged Sedation in Critically Ill Patients With COVID-19-Associated Acute Respiratory Distress Syndrome.
Topics: Aged; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; Critical Illness; Dee | 2022 |
15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study.
Topics: Age Factors; Aged; Betacoronavirus; China; Coronavirus Infections; COVID-19; Critical Illness; Drug | 2020 |
Computerized physician order entry of a sedation protocol is not associated with improved sedation practice or outcomes in critically ill patients.
Topics: Adult; Aged; Analgesics; Cohort Studies; Critical Illness; Dose-Response Relationship, Drug; Female; | 2015 |
Outcomes of Patients with Alcohol Withdrawal Syndrome Treated with High-Dose Sedatives and Deferred Intubation.
Topics: Adult; Alcohol Withdrawal Seizures; APACHE; Central Nervous System Depressants; Cohort Studies; Crit | 2016 |
Valproate for agitation in critically ill patients: A retrospective study.
Topics: Adult; Aged; Analgesics, Opioid; Critical Illness; Delirium; Dexmedetomidine; Female; Fentanyl; GABA | 2017 |
A Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill.
Topics: Adult; Benzodiazepines; Clinical Protocols; Critical Illness; Dose-Response Relationship, Drug; Drug | 2017 |
Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.
Topics: Adult; Age Factors; Aged; Critical Illness; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 2009 |
The complex interplay between delirium, sepsis and sedation.
Topics: Brain; Critical Illness; Delirium; Dexmedetomidine; Humans; Hypnotics and Sedatives; Intensive Care | 2010 |
Diazepam as a component of goal-directed sedation in critically ill trauma patients.
Topics: Adult; APACHE; Critical Illness; Diazepam; Drug Interactions; Drug Therapy, Combination; Female; Hum | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Sleep disturbances in the critically ill patients: role of delirium and sedative agents.
Topics: Aged; Critical Illness; Delirium; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle A | 2011 |
Bispectral index values, sedation-agitation scores, and plasma Lorazepam concentrations in critically ill surgical patients.
Topics: Adult; Aged; Conscious Sedation; Consciousness Monitors; Critical Illness; Electromyography; Female; | 2012 |
Medication vehicle injury--using the proper restraint?
Topics: Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Huma | 2004 |
Propylene glycol accumulation after high-dose lorazepam: what have we learned?
Topics: Acid-Base Equilibrium; Acidosis; Critical Illness; Humans; Hypnotics and Sedatives; Infusions, Intra | 2005 |
Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients.
Topics: Costs and Cost Analysis; Critical Illness; Decision Support Techniques; Economics, Pharmaceutical; H | 2005 |
Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient.
Topics: Aged; Bacterial Infections; Coma; Critical Illness; Diagnosis, Differential; Diazepam; Flumazenil; H | 1994 |
The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients.
Topics: Aged; Analgesics, Opioid; APACHE; Carbon Dioxide; Cardiac Output; Critical Illness; Female; Hemodyna | 1996 |
A method to produce sedation in critically ill patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Anti-Anxiety Agents; APACHE; Apnea; Child; Conscious Sedation | 1996 |
A cost analysis of enterally administered lorazepam in the pediatric intensive care unit "out of the orphanage".
Topics: Child; Cost-Benefit Analysis; Critical Illness; Humans; Hypnotics and Sedatives; Intensive Care Unit | 1999 |
A cost analysis of enterally administered lorazepam in the pediatric intensive care unit.
Topics: Child; Child, Preschool; Cost-Benefit Analysis; Critical Illness; Drug Costs; Female; Hospital Costs | 1999 |
Pharmacokinetics of lorazepam in critically ill neonates with seizures.
Topics: Critical Illness; Humans; Infant, Newborn; Injections, Intravenous; Lorazepam; Seizures | 1992 |